The challenge of cross-trial comparisons using limited data

Ítems similars

• Reply to “The challenge of cross-trial comparison using limited data” Haematologica. 2014;99(8):e000
  per: Siegel, David S.
  Publicat: (2014)
• Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy
  per: Voorhees, Peter M., et al.
  Publicat: (2013)
• Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
  per: LAUBACH, JACOB P., et al.
  Publicat: (2009)
• A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma
  per: Laubach, Jacob P., et al.
  Publicat: (2017)
• Cross-talk between the heart and cancer – beyond drug toxicity
  per: Moslehi, Javid, et al.
  Publicat: (2020)